Vaccination against tuberculosis. / Vacunación frente a tuberculosis.
Enferm Infecc Microbiol Clin (Engl Ed)
; 36(10): 648-656, 2018 Dec.
Article
en En, Es
| MEDLINE
| ID: mdl-29627126
ABSTRACT
BCG (Bacille Calmette-Guérin) vaccination is included in the immunization schedule for tuberculosis endemic countries with a global coverage at birth close to 90% worldwide. BCG was attenuated from Mycobacterium bovis almost a century ago, and provides a strong protection against disseminated forms of the disease, though very limited against pulmonary forms of tuberculosis, responsible for transmission. Novel prophylactic tuberculosis vaccines are in clinical development either to replace BCG or to improve its protection against respiratory forms of the disease. There are limitations understanding the immunological responses involved and the precise type of long-lived immunity that new vaccines need to induce. MTBVAC is the first and only tuberculosis vaccine candidate based on live-attenuated Mycobacterium tuberculosis in clinical evaluation. MTBVAC clinical development plans to target tuberculosis prevention in newborns, as a BCG replacement strategy, and as secondary objective to be tested in adolescents and adults previous vaccinated with BCG.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
2_ODS3
/
3_ND
/
4_TD
Problema de salud:
1_doencas_transmissiveis
/
2_enfermedades_transmissibles
/
3_neglected_diseases
/
3_tuberculosis
/
3_zoonosis
/
4_tuberculosis
Asunto principal:
Tuberculosis
/
Vacuna BCG
/
Vacunación
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
/
Es
Revista:
Enferm Infecc Microbiol Clin (Engl Ed)
Año:
2018
Tipo del documento:
Article